Abstract
Proteases are essential enzymes which regulate physiological processes such as inflammation, infection, fertilization, allergic reactions, cell growth and death, blood clotting, tumor growth and bone remodeling. The protease family consists of six major classes of enzymes which are aspartic-, serine-, cysteine-, threonine-, glutamic-, and metalloproteases, all which are implicated in disease propagation. Therefore, protease inhibitors have been of great interest as possible targets for the development of novel therapies. Although, many protease inhibitors have followed a structural design based on either a peptidic or peptidomimetic backbone, other chemical scaffolds have recently emerged. Utilizing structure- and fragment-based design guided by X-ray crystallography, NMR spectroscopy, computational and/or extended tethering approaches, potential non-peptidic therapeutic agents could be identified. In this review, we will report on the recent developments of nonpeptidic cysteine- and metallo- protease inhibitors, focusing on their design by using such strategies.
Keywords: Cysteine proteases, benzodioxane derivative (BI-7E7), NMR-based screening, computational docking methods, Cathepsin Inhibitors, Matrix Metallo-protease Inhibitors
Current Topics in Medicinal Chemistry
Title: Structure- and Fragment-Based Approaches to Protease Inhibition
Volume: 6 Issue: 4
Author(s): Sherida L. Johnson and Maurizio Pellecchia
Affiliation:
Keywords: Cysteine proteases, benzodioxane derivative (BI-7E7), NMR-based screening, computational docking methods, Cathepsin Inhibitors, Matrix Metallo-protease Inhibitors
Abstract: Proteases are essential enzymes which regulate physiological processes such as inflammation, infection, fertilization, allergic reactions, cell growth and death, blood clotting, tumor growth and bone remodeling. The protease family consists of six major classes of enzymes which are aspartic-, serine-, cysteine-, threonine-, glutamic-, and metalloproteases, all which are implicated in disease propagation. Therefore, protease inhibitors have been of great interest as possible targets for the development of novel therapies. Although, many protease inhibitors have followed a structural design based on either a peptidic or peptidomimetic backbone, other chemical scaffolds have recently emerged. Utilizing structure- and fragment-based design guided by X-ray crystallography, NMR spectroscopy, computational and/or extended tethering approaches, potential non-peptidic therapeutic agents could be identified. In this review, we will report on the recent developments of nonpeptidic cysteine- and metallo- protease inhibitors, focusing on their design by using such strategies.
Export Options
About this article
Cite this article as:
Johnson L. Sherida and Pellecchia Maurizio, Structure- and Fragment-Based Approaches to Protease Inhibition, Current Topics in Medicinal Chemistry 2006; 6 (4) . https://dx.doi.org/10.2174/156802606776287072
DOI https://dx.doi.org/10.2174/156802606776287072 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dopaminergic Enhancement of Cognitive Function
Current Pharmaceutical Design Anti-Seizure Medications and Estradiol for Neuroprotection in Epilepsy: The 2013 Update
Recent Patents on CNS Drug Discovery (Discontinued) Endocannabinoid Regulation of Matrix Metalloproteinases: Implications in Ischemic Stroke
Cardiovascular & Hematological Agents in Medicinal Chemistry Neutralization of Interleukin-1β Reduces Vasospasm and Alters Cerebral Blood Vessel Density Following Experimental Subarachnoid Hemorrhage in Rats
Current Neurovascular Research Inflammation Drives Alzheimer's Disease: Emphasis on 5-lipoxygenase Pathways
Current Neuropharmacology Phase II and Pharmacological Study of Oral Docetaxel Plus Cyclosporin A in Anthracycline Pre-Treated Metastatic Breast Cancer
Current Clinical Pharmacology <i>Arctium Lappa</i> and Management of Liver Functions to Detoxify the Bloodstream
The Natural Products Journal Measurement of Palmitoylethanolamide and Other N-Acylethanolamines During Physiological and Pathological Conditions
CNS & Neurological Disorders - Drug Targets Chromogranin A and the Endothelial Barrier Function
Current Medicinal Chemistry Pleiotropic Actions of PPARg Activators Thiazolidinediones in Cardiovascular Diseases
Current Pharmaceutical Design Editorial (Thematic Issue: New Therapeutic Targets in Clinical Medicine)
Current Pharmaceutical Design Possibilities of Poly(D,L-lactide-co-glycolide) in the Formulation of Nanomedicines Against Cancer
Current Drug Targets The Influence of Erythropoietin and Proinflammatory Cytokines in the Development of Cerebral Palsy
Vascular Disease Prevention (Discontinued) Mitochondrial Permeability Transition Pore as a Suitable Targ e t for Neuroprotective Agents Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Gender Hormones: Role in the Pathogenesis of Central Nervous System Disease and Demyelination
Current Neurovascular Research LFA-1 as a Key Regulator of Immune Function: Approaches toward the Development of LFA-1-Based Therapeutics
Current Pharmaceutical Design New Molecular Targets in the Treatment of NSCLC
Current Pharmaceutical Design Xuesaitong May Protect Against Ischemic Stroke by Modulating Microglial Phenotypes and Inhibiting Neuronal Cell Apoptosis via the STAT3 Signaling Pathway
CNS & Neurological Disorders - Drug Targets Genistein as a Potential Anticancer Agent Against Head and Neck Squamous Cell Carcinoma
Current Topics in Medicinal Chemistry Psoriasis in Children: A Review
Current Pediatric Reviews